Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity

Rajiv Jash; Chiranjib Bagchi; Achintya Mitra; Santanu Kumar Tripathi

doi:10.5455/njppp.2022.12.08304202101092021

2024, Vol: 14, Issue: 4

14 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
14 / 09 / 2021

Natl J Physiol Pharm Pharmacol. 2022; 12(3): 289-295

doi: 10.5455/njppp.2022.12.08304202101092021

Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity

Rajiv Jash, Chiranjib Bagchi, Achintya Mitra, Santanu Kumar Tripathi.

Abstract
Background: Gugulipid obtained from Commiphora mukul carries a long history of safe and efficacious use in hyperlipidemia as per Ayurvedic literature. Statins like atorvastatin are a highly prescribed hypolipidemic drug but not free from potentially serious adverse effects.

Aims and Objectives: The present study was designed to establish antihyperlipidemic activity of gugulipid in triton-induced hyperlipidemic rats in comparison to atorvastatin and simultaneously to explore the combination of gugulipid and atorvastatin for any synergistic activity.

Materials and Methods: Male Wistar albino rats (20) were divided equally into vehicle (2% gum acacia) (Group I), gugulipid only 6.75 mg/kgbw (Group II), atorvastatin 7.2 mg/kgbw only (Group III), and gugulipid 6.75 mg/kgbw and atorvastatin in 7.2 mg/kgbw combination (Group IV) in Phase 1 study. In Phase 2, additional three groups were created with five rats in each receiving gugulipid 6.75 mg/kgbw with atorvastatin at 5.4 mg/kgbw, 3.6 mg/kgbw, and 1.8 mg/kgbw dosage, respectively (Groups VVII). Hyperlipidemia was induced by single intraperitoneal injection (400 mg/kgbw) of triton after 7 days of feeding with respective agents dissolved in vehicle through oral route.

Results: Regarding total cholesterol (TC), triglyceride (TG), and low-density lipoprotein (LDL), Gr II was found superior to Gr I but inferior to others (P < 0.01). Gr IV prevented the rise of TC and TG significantly in comparison to Gr V, VI, and VII (P < 0.01) whereas Groups V and VI having non-significant difference in between, both differed significantly (P < 0.01) with Gr VII. Groups IV, V, and VI prevented the rise of serum LDL significantly (P < 0.01) from Group VII.

Conclusion: Gugulipid showed significant antihyperlipidemic activity and was found to be optimally efficacious and safe in combination with even reduced dose of atorvastatin.

Key words: Hypolipidemic; Antihyperlipidemic; Triton; Hyperlipidemic; Gugulipid; Atorvastatin; Drug Synergism

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Rajiv Jash Articles by Chiranjib Bagchi Articles by Achintya Mitra Articles by Santanu Kumar Tripathi
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Jash R, Bagchi C, Mitra A, Tripathi SK. Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. Natl J Physiol Pharm Pharmacol. 2022; 12(3): 289-295. doi:10.5455/njppp.2022.12.08304202101092021

Web Style

Jash R, Bagchi C, Mitra A, Tripathi SK. Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. https://www.njppp.com/?mno=114616 [Access: March 14, 2024]. doi:10.5455/njppp.2022.12.08304202101092021

AMA (American Medical Association) Style

Jash R, Bagchi C, Mitra A, Tripathi SK. Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. Natl J Physiol Pharm Pharmacol. 2022; 12(3): 289-295. doi:10.5455/njppp.2022.12.08304202101092021

Vancouver/ICMJE Style

Jash R, Bagchi C, Mitra A, Tripathi SK. Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. Natl J Physiol Pharm Pharmacol. (2022), [cited March 14, 2024]; 12(3): 289-295. doi:10.5455/njppp.2022.12.08304202101092021

Harvard Style

Jash, R., Bagchi, . C., Mitra, . A. & Tripathi, . S. K. (2022) Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. Natl J Physiol Pharm Pharmacol, 12 (3), 289-295. doi:10.5455/njppp.2022.12.08304202101092021

Turabian Style

Jash, Rajiv, Chiranjib Bagchi, Achintya Mitra, and Santanu Kumar Tripathi. 2022. Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. National Journal of Physiology, Pharmacy and Pharmacology, 12 (3), 289-295. doi:10.5455/njppp.2022.12.08304202101092021

Chicago Style

Jash, Rajiv, Chiranjib Bagchi, Achintya Mitra, and Santanu Kumar Tripathi. "Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 289-295. doi:10.5455/njppp.2022.12.08304202101092021

MLA (The Modern Language Association) Style

Jash, Rajiv, Chiranjib Bagchi, Achintya Mitra, and Santanu Kumar Tripathi. "Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity." National Journal of Physiology, Pharmacy and Pharmacology 12.3 (2022), 289-295. Print. doi:10.5455/njppp.2022.12.08304202101092021

APA (American Psychological Association) Style

Jash, R., Bagchi, . C., Mitra, . A. & Tripathi, . S. K. (2022) Evaluation of antihyperlipidemic activity of gugulipid alone and in combination with different dosage of atorvastatin in triton-induced hyperlipidemic rodent model: Exploring a possible synergistic activity. National Journal of Physiology, Pharmacy and Pharmacology, 12 (3), 289-295. doi:10.5455/njppp.2022.12.08304202101092021

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272